Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Teva Pharmaceutical Industries Limited (TEVA)

43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025, 11:15 AM ET

Company Participants

Richard Francis - President and CEO

Eric Hughes - Head of R&D and Chief Medical Officer

Conference Call Participants

Chris Schott - J.P. Morgan

Presentation

Chris Schott

Good morning, everybody. I'm Chris Schott from J.P. Morgan and it's my pleasure to be introducing Teva today at the J.P. Morgan Healthcare Conference. From the company we have the CEO, Richard Francis. Richard joined Teva, I guess about two years ago and it's been a very productive couple of years as a great stock performance, and looking forward ...

SA Transcripts on Seeking Alpha | January 13, 2025

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S.Partnership supports Teva's Pivot to Growth strategy and adds to its broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ha

Yahoo | January 10, 2025

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

NMRA and HOTH are in the spotlight in the biotech sector on study data announcement.

Yahoo | January 9, 2025

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical

On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.A in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Firdapse (amifampridine) 10 mg tablets before the expiration of the applicable patents. If approved by the FDA, Teva will not market its generic versi

Yahoo | January 9, 2025

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.

Yahoo | January 9, 2025

IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Yahoo | January 8, 2025

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.6% and the He

Yahoo | January 8, 2025

Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday

We recently compiled a list of the 10 Firms Kick Off 2025 Trading in The Red. In this article, we are going to take a look at where Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) stands against the other stocks. The stock market finished the first trading day of the year in the negative territory—a fifth straight day, […]

Yahoo | January 3, 2025

Teva Pharmaceutical Industries Ltd (TEVA) Ends Trading Week Defying Market Bloodbath

We recently compiled a list of the 10 Firms End Trading Week Defying Market Bloodbath. In this article, we are going to take a look at where Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing major indices lower as investors shifted capital towards more […]

Yahoo | December 28, 2024

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025

Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI) stocks in favor of a drugmaker whose shares are up by 112% for the year.

Yahoo | December 24, 2024